CTMX vs TPST

Analysts rate CytomX Therapeutics, Inc.

(CTMX) a "Buy" — based on 21 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, CytomX Therapeutics, Inc.

(CTMX) delivered a total return of -53. 2%, compared to -88. 0% for Tempest Therapeutics, Inc. (TPST). Over 10 years, the gap is even starker: CTMX returned -67. 1% versus TPST's -99. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), CytomX Therapeutics, Inc.

(CTMX) is the lower-risk stock at 1. 47β versus Tempest Therapeutics, Inc. 's 1. 61β — meaning TPST is approximately 9% more volatile than CTMX relative to the S&P 500. On balance sheet safety, CytomX Therapeutics, Inc. (CTMX) carries a lower debt/equity ratio of 4% versus 80% for Tempest Therapeutics, Inc. — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: Tempest Therapeutics, Inc.

grew EPS 21. 5% year-over-year, compared to -139. 5% for CytomX Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Tempest Therapeutics, Inc.

(TPST) is the more profitable company, earning 0. 0% net margin versus -22. 8% for CytomX Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TPST leads at 0. 0% versus -25. 7% for CTMX. At the gross margin level — before operating expenses — CTMX leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, CTMX (0.

5% yield) pays a dividend. TPST does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, CytomX Therapeutics, Inc.

(CTMX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (0. 5% yield). Tempest Therapeutics, Inc. (TPST) carries a higher beta of 1. 61 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CTMX: -67. 1%, TPST: -99. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

CTMX pays a dividend while TPST does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.